<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The cryopyrin-associated <z:e sem="disease" ids="C0585274" disease_type="Disease or Syndrome" abbrv="">periodic syndrome</z:e> (CAPS) is a rare but treatable hereditary autoinflammatory condition </plain></SENT>
<SENT sid="1" pm="."><plain>Without treatment, one third of patients develop <z:hpo ids='HP_0011034'>amyloidosis</z:hpo> with consequent <z:hpo ids='HP_0000083'>renal failure</z:hpo> and <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>CAPS encompasses 3 conditions: <z:e sem="disease" ids="C1610600" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">familial cold autoinflammatory syndrome</z:e>, <z:e sem="disease" ids="C0268390" disease_type="Disease or Syndrome" abbrv="">Muckle-Wells syndrome</z:e>, and <z:hpo ids='HP_0011010'>chronic</z:hpo> infantile, neurologic, cutaneous, and articular syndrome </plain></SENT>
<SENT sid="3" pm="."><plain>Neurologic complications are common in children with the <z:hpo ids='HP_0011010'>chronic</z:hpo> infantile, neurologic, cutaneous, and articular phenotype, but there are no previous published reports of neurologic features in adults with milder phenotypes </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: In this case series, we report in detail an adult case of CAPS and summarize the neurologic features seen in 12 other adults with genetically proven CAPS </plain></SENT>
<SENT sid="5" pm="."><plain>These patients participated in a recent randomized study of canakinumab in CAPS and we used pretreatment data collected in this study </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Twelve of the 13 patients (92%) had <z:hpo ids='HP_0002315'>headache</z:hpo>, of whom 10 (77%) had features of <z:hpo ids='HP_0002076'>migraine</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Seven patients (54%) had <z:hpo ids='HP_0000407'>sensorineural deafness</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Nine patients (69%) reported <z:hpo ids='HP_0003326'>myalgia</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Six patients (46%) had <z:hpo ids='HP_0001085'>papilledema</z:hpo> and a further 2 (15%) had <z:hpo ids='HP_0000543'>optic disc pallor</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>MRI brain scan was <z:mpath ids='MPATH_458'>normal</z:mpath> in <z:hpo ids='HP_0000001'>all</z:hpo> patients </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: CAPS is a rare but treatable condition that may be encountered by neurologists in adult clinical practice since it can present with <z:hpo ids='HP_0002315'>headache</z:hpo>, <z:hpo ids='HP_0003326'>myalgia</z:hpo>, <z:hpo ids='HP_0001085'>papilledema</z:hpo>, <z:hpo ids='HP_0000407'>sensorineural deafness</z:hpo>, and aseptic <z:hpo ids='HP_0001287'>meningitis</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>Unrecognized and untreated, it can lead to significant morbidity and mortality from <z:hpo ids='HP_0000083'>renal failure</z:hpo> </plain></SENT>
<SENT sid="13" pm="."><plain>Treatment with anti-interleukin-1 therapy leads to complete resolution of symptoms and should also prevent progression to <z:hpo ids='HP_0011034'>amyloidosis</z:hpo> and subsequent <z:hpo ids='HP_0000083'>renal failure</z:hpo> </plain></SENT>
</text></document>